FMP

FMP

Enter

GNCA - Genocea Biosciences, Inc.

Profile of Genocea Biosciences, Inc.(GNCA), Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunoth

photo-url-https://financialmodelingprep.com/image-stock/GNCA.jpg

Genocea Biosciences, Inc.

GNCA

NASDAQ

0.0001 USD

-0.0006 (-600%)

About

ceo

Mr. William Clark

sector

Healthcare

industry

Biotechnology

website

https://www.genocea.com

exchange

NASDAQ

Description

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

CIK

0001457612

ISIN

US3724274010

CUSIP

372427401

Address

100 Acorn Park Dr

Phone

16178768191

Country

US

Employee

74

IPO Date

Feb 5, 2014

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep